EGFR and non-small cell lung carcinoma: Taken together, our results, for the first time, suggest that the combination treatment of theasinensin A and nimotuzumab is active against wild-type EGFR NSCLC cells via the induction of EGFR degradation and the inhibition of downstream survival pathways.